Exogenous surfactant therapy is widely used for the prevention and treatmen
t of respiratory distress syndrome in premature newborns. The introduction
of surfactant therapy is widely credited with recent improvements in neonat
al mortality. This article presents an overview of the current use of exoge
nous surfactant therapy for preterm neonates, based on currently available
evidence.